OBJECTIVE:Pneumocystis jirovecii pneumonia is a serious opportunistic infection in immunocompromised individuals. Despite recognized person-to-person transmission and healthcare-associated outbreaks, optimal infection control strategies remain unclear. The COVID-19 pandemic led to the implementation of universal masking and physical distancing in hospitals, providing a unique setting to observe P. jirovecii transmission under stringent "droplet precaution"-like conditions. This study investigated healthcare-associated P. jirovecii transmission between June 2020 and November 2021. DESIGN:Retrospective cohort study. SETTING:One tertiary-care hospital in Montréal, QC, Canada. PATIENTS:All patients with P. jirovecii pneumonia at our institution during that period. METHODS:Cases were identified via laboratory data and chart review. P. jirovecii-positive samples underwent genotyping using multilocus sequence typing. A transmission map was constructed based on shared genotypes and spatiotemporal overlap of hospital visits within a defined window of potential exposure. RESULTS:Twenty-eight P. jirovecii pneumonia cases were identified. Genotyping succeeded at providing a distinct sequence type (ST) in 21 cases, revealing 7 patients with shared genotypes (3 with ST52, 2 with STX7, 2 with ST19). The transmission map of 12 patients with shared or unknown genotypes revealed 34 same-day and 34 within-one-day contacts, exclusively within outpatient clinics and imaging facilities. Three spatiotemporal clusters of plausible healthcare-associated transmission were identified despite universal masking. CONCLUSION:The occurrence of plausible healthcare-associated P. jirovecii transmission despite stringent universal masking suggests that traditional "droplet precautions" alone may be insufficient to prevent spread, supporting airborne transmission. Infection prevention strategies may need to be expanded in high-risk settings and should account for airborne transmission.
Background:In 2024-25, Quebec implemented a universally publicly funded infant nirsevimab program. We estimated effectiveness, number-needed-to-immunize (NNI) and impact against severe respiratory syncytial virus (RSV) outcomes. Methods:A test-negative study estimated adjusted effectiveness among nirsevimab-eligible children RSV-tested during emergency room (ER) consultation or hospitalization between October 2024 and March 2025. Eligible children were born during the RSV season (at-birth group) or <6- to <19-month-olds healthy, preterm, with chronic conditions or living in remote regions (catch-up groups). We used 2023-24 respiratory hospitalization rates, RSV-positivity from a systematic hospital-based surveillance network, and Quebec 2024-25 coverage estimates to derive the theoretical NNI and averted hospitalizations. Findings:Effectiveness analyses included 3172 specimens linked to ER consultations (1775 [56·0%] from male and 1397 [44·0%] from female participants; 668 [21·1%] RSV-positive) and 1758 linked to hospitalizations (988 [56·2%] from male and 770 [43·8%] from female participants; 549 [31·2%] RSV-positive). Effectiveness was 86% (95% CI: 82-90) against ER consultation, 89% (95% CI: 84-92) against hospitalization (79% (95% CI: 60-89) for those with chronic diseases and 93% (95% CI: 83-97) for preterm infants), and 88% (95% CI: 58-97) against ICU admission. We estimated 41 at-birth and 58 catch-up immunizations needed to avert one RSV-associated hospitalization. We estimated that 72% (at-birth group) and 59% (catch-up group with 64% coverage by November) of RSV-associated hospitalizations were prevented, potentially increasing to 82% for a hypothetical coverage of 90% by October. Interpretation:Nirsevimab is highly effective and could more substantially impact the RSV burden through broad and timely administration to healthy-term and high-risk infants. Funding:Ministère de la santé et des services sociaux du Québec.
Background: Assisted reproductive technology has been linked to an increased risk of pregnancy-related cardiovascular complications, but the long-term cardiovascular outcome is poorly understood. This study aimed to assess whether women who use ART have an elevated long-term risk of adverse cardiovascular outcomes. Methods: We conducted a systematic review and meta-analysis to examine the association between ART and long-term cardiovascular outcomes after pregnancy. We systematically searched MEDLINE, Embase, and the Cochrane Library for studies published by January 2026. We evaluated the methodological quality of included studies using the Newcastle-Ottawa Scale. We used random effects models to calculate pooled adjusted risk ratios (aRR) with 95% confidence intervals (CI) for the association of ART with cardiovascular outcomes. Results: We included thirteen studies comprising 553,331 patients who used ART and 37,826,591 patients who conceived spontaneously. All women achieved a live birth. Mean duration of follow-up after delivery was 8.4 ± 8.3 years. In models adjusted for age, parity, and comorbidity, ART was associated with a small increase in the risk of cardiovascular disease compared with spontaneous conception (aRR 1.18, 95% CI 1.03-1.35), but the association was attenuated when studies that had only 42 days of follow-up were excluded (aRR 1.13, 95% CI 0.99-1.29). ART was not associated with cardiac complications (aRR 0.94, 95% CI 0.82-1.08), stroke (aRR 1.20; 95% CI 0.93-1.55), hypertension (aRR 1.02; 95% CI 0.72-1.44), or venous thrombosis (aRR 1.27, 95% CI 0.97-1.67). Conclusions: Our findings suggest that women who achieve a live birth following ART do not appear to have an increased long-term risk of adverse cardiovascular outcomes. These results provide reassuring evidence for patient counseling regarding the long-term cardiovascular safety of ART among women with successful pregnancies. Further research that includes women who do not achieve a live birth is warranted to more fully characterize the potential long-term cardiovascular effects of ART across the entire spectrum of treatment outcomes.
Le programme de surveillance des souches de Neisseria gonorrhoeae résistantes aux antibiotiques a été mis en place en 1988 dans la province de Québec. Le présent rapport fait état des résultats des analyses effectuées par le Laboratoire de santé publique du Québec (LSPQ) sur les souches de Neisseria gonorrhoeae isolées au cours des années 2023 et 2024 et décrit l’évolution temporelle de la résistance. Il a été élaboré à la demande du ministère de la Santé et des Services sociaux du Québec dans le cadre d’un mandat de surveillance. Ce rapport de surveillance présente les résultats obtenus en 2023 et 2024 et compare ceux-ci avec certains résultats obtenus depuis 2015. Il s’adresse principalement aux microbiologistes-infectiologues, aux cliniciens du réseau et aux professionnels des directions de santé publique. Il vise à soutenir les cliniciens ainsi que les intervenants dans le domaine des infections transmissibles sexuellement et par le sang.
Ce rapport de surveillance porte sur les lésions professionnelles attribuables à une exposition aux vibrations main-bras, déclarées et indemnisées au Québec par la Commission des normes, de l’équité, de la santé et de la sécurité du travail entre 1997 et 2022. L’objet du rapport est de décrire ces lésions selon les caractéristiques des travailleuses et travailleurs concernés, les circonstances de l’exposition aux vibrations main-bras à l’origine de ces lésions, et les conséquences qui en découlent. Il a été élaboré en vertu de l’entente spécifique avec le ministère de la Santé et des services sociaux (MSSS) portant sur la surveillance de l’état de santé de la population en emploi et de ses déterminants. Cette surveillance est prévue dans l’entente-cadre visant à développer et consolider une expertise en santé publique permettant de soutenir le MSSS. Ce document s’adresse à divers acteurs de santé publique, notamment en santé au travail, dans une optique de prévention des effets néfastes des vibrations sur la santé des travailleuses et des travailleurs du Québec qui y sont exposés.